Bayer Rises as BofAML Predicts New Drug Success: Frankfurt Mover

Bayer AG (BAYN) rose to a record after Bank of America Merrill Lynch put the the German drugs and chemicals maker on its list of top European stocks, citing confidence in its drug pipeline and agriculture unit.

The shares rose as much as 5 percent, the steepest intraday gain since June 29, and traded 4.5 percent higher at 75.71 euros as of 12:50 p.m. in Frankfurt. Bayer has returned 48 percent in the past 12 months, including reinvested dividends, amid a series of drug-development successes for the Leverkusen-based company’s health-care unit.

“Strong execution” as Bayer begins to sell new medicines this year will probably boost investors’ confidence that Bayer will get more than 5.5 billion euros ($7.4 billion) in annual sales from the drug introductions, Sachin Jain and Graham Parry, the London-based analysts at Merrill Lynch, wrote in a note to investors today. Average analyst expectations are for 3 billion euros in 2016 sales from new drugs, the analysts wrote.

Investors may be underestimating the potential of its CropScience division this year, the analysts also wrote. Their estimate for the unit’s earnings before interest, taxes, depreciation and amortization is about 15 percent higher than the average, they said.

Bayer made progress last year with blood thinner Xarelto, eye drug Eylea, lung treatment riociguat, colorectal cancer medicine Stivarga and prostate cancer drug Alpharadin. The company gave its peak annual sales forecast of 5.5 billion euros for the new drugs in November.

Bayer announces fourth-quarter earnings on Feb. 28.

To contact the reporter on this story: Naomi Kresge in Berlin at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.